Employer-mandated high-deductible health plan enrollment was not associated with reduced use of oral targeted anticancer ...
CMS is adding value-based care (VBC) risk faster than many providers can build the data and tech capacity they need to ...
Gray market peptides cause vague symptoms patients may not disclose or link, so serious harms can go unnoticed until late, ...
Goad, PharmD, MPH, of Chapman University explains why pharmacists are trusted, accessible sources for COVID-19 vaccine ...
MA-to-MA switching among dually eligible beneficiaries rose sharply from 2016 to 2022, AJMC study author Grace Mackleby, PhD, ...
Telitacicept has the first regulatory approval for Sjögren disease (China), while global phase 3 programs aim to support ...
FDA authorized frontline pirtobrutinib for previously untreated CLL/SLL without known 17p deletion, expanding use beyond its established relapsed/refractory setting after covalent BTK inhibition.
Weekly survodutide 3.6 mg/6.0 mg achieved up to 13.1% mean weight loss at week 76 versus 3.1% with placebo, meeting ...
A finalized mandatory model will test whether tying Medicare Part B drug rebates to international prices can lower costs for ...
Lung cancer screening eligibility increased markedly from 2018–2023 under USPSTF criteria, reflecting aging and substantial ...
Susan Sabo-Wagner, MSN, RN, OCN, NEA-BC, discusses how data builds payer trust, reduces prior authorization, and expands access in community oncology. Sustainable models require asking what a result ...
Both 340B stakeholders endorsed an independent data clearinghouse and statutory patient definition amid program growth ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results